Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Los términos de búsqueda han de ser en inglés.

Compuestos neuroprotectores

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOES20150820001
Publicado:
26/08/2015
Caducidad:
25/08/2016
Resumen:
Un instituto español de investigación médica ha obtenido nuevas piridodiacepinas con actividad de bloqueo del intercambiador sodio/calcio mitocondrial que se utilizan como compuestos neuroprotectores en patologías del sistema nervioso, como Alzheimer, Parkinson, esclerosis lateral amiotrófica, dolor y epilepsia. Estos compuestos presentan un perfil neuroprotector en neuronas y tejidos nerviosos sometidos a estímulos tóxicos relacionados con la neurodegeneración. Se buscan socios para establecer acuerdos de licencia o cooperación en materia de investigación.

Details

Tittle:
Neuroprotective compounds.
Summary:
A Spanish health research institute has obtained new pyridothiazepines with blocking activity of the mitochondrial sodium/calcium exchanger, to be used as neuroprotective compounds on nervous system pathologies like Alzheimer, Parkinson, Amyotrophyc lateral esclerosis, pain, epilepsy.
They are looking for partners to license the product or for research cooperation agreements.
Description:
Mitochondria are the energy-productin factory of eukariotic cells. In addition, they play a fundamental role in the clearance of the cytosolic calcium. Upon cells tymulationi, mitochondria are capable of accumulating vast amounts of calcium int their matrix through the calcium uniporter. After cell stimulation ceases, the calcium accumulated in the mitochondrial matrix is then released back into the cytosol thorough antiporters line the sodium/calcium exchanger (mNCX). A minimal cytosolic calcium level is required to mantain neuronal viability, when this calcium moves below or above a set-point, apoptosis is rapidly induced and the death of neurons occurs. The research group explored the possibility that the mitigation of the rate of mitochondrial calcium efflux to the cytosol by the mNCX blocker CGP37157 could afford neuroprotection against neurotoxicity elicited by cell calcium overload. This blocker has also shown blocking activities against other channels and modulators. So mNCX was the target for developing these new neuroprotective agents, with more selectivity and potency than the ones that have been discovered until now, by blocking its activity. Its therapeutic activity could be useful against neurodegenerative diseases, stroke, and diabetes among others where the function of mNCX is compromised.
The research group of the Spanish health research institue found these compounds that showed a decent blockade of the clearance of mitochondrial calcium, as well as an important neuroprotective profile against toxic models of neurodegeneration, related to calcium overload and mitochondrial disfunction.
They are looking for biopharmaceutical companies to license the compounds and introduce them into their portforlio. Another envisaged cooperation could be under research cooperation agreements in order to develop together new treatments mainly for neurodegenerative diseases.
Advantages and Innovations:
The compounds are blockers of the mitochondrial sodium/calcium exchanger better than the best-known like CGP37157, used since the 1980´s.
These new compounds show neuroprotective profile in neurons and nerve tissues subjected to toxic stimuli related to neurodegeneration.
Stage of Development:
Under development/lab tested
IPs:
Patent(s) applied for but not yet granted
CommeR Statunts Regarding IPR Status:
Spanish patent application filed on July 2015

Partner sought

Type and Role of Partner Sought:
The Spanish health research institute is looking for biopharmaceutical companies interested in establishing research alliances in order to continue together with the identification and development of treatments against neurodegenerative diseases, or licensing the compounds found.

Client

Type and Size of Client:
R&D Institution
Already Engaged in Trans-National Cooperation:
No
Languages Spoken:
English
Italian
Spanish

Keywords

Technology Keywords:
06001014 Neurología, investigación cerebral
06001015 Productos farmacéuticos / medicamentos